HCRN-GU16-287
Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer Status: Closed to […]
Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer Status: Closed to […]
Families who fight cancer along with their ailing loved one grapple with many issues, from health decisions and a myriad of emotions to logistical and […]
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252 Status: Closed to Accrual
Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer Status: Closed to Accrual
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High […]
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma […]
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
Three HCRN investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting held virtually June 4-8. Deepak Kilari, MD, […]
A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer
This month, Hoosier Cancer Research Network features our member institution Fox Chase Cancer Center, and Daniel M. Geynisman, MD, associate professor, Hematology/Oncology and a medical […]
Hoosier Cancer Research Network (HCRN) received the Indiana Cancer Consortium (ICC) Sustained Excellence Award during the ICC’s 2021 Annual Meeting on April 21. The award […]
A Translational Breast Cancer Research Consortium (TBCRC) study was presented at both the 2021 San Antonio Breast Cancer Symposium and the American Society for Radiation […]
This month, Hoosier Cancer Research Network features our member institution Cleveland Clinic Cancer Center and medical oncologist Shilpa Gupta, MD. Dr. Gupta is a genitourinary […]
Hoosier Cancer Research Network recently welcomed Vivian Cintron, PhD, MBA, as its first chief operating officer. In her new role, she will work closely with […]
Hoosier Cancer Research Network announces the appointment of Shilpa Gupta, MD, of the Cleveland Clinic, and Rana McKay, MD, of the University of California San […]
Abstracts from four Hoosier Cancer Research Network studies have been accepted by the American Society of Clinical Oncology (ASCO) for the 2015 Annual Meeting in […]
A Phase II Trial of ZD1839 (IRESSA®) in Both Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers
A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)
Abstracts from three Hoosier Cancer Research Network studies were accepted to the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, June 2-6 at the McCormick […]
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter